Juncell Therapeutics to Present Preclinical Data on Innovative Pretreatment Regimen of TIL Therapy at AACR Annual Meeting 2025
SHANGHAI, March 26, 2025 /PRNewswire/ -- Shanghai Juncell Therapeutics Co., Ltd. (Juncell Therapeutics), a clinical-stage biotech developing innovative IL-2-independent Tumor-Infiltrating Lymphocyte (TIL) therapies for cancers, announced that a...
